Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA

Jianjian Gao, Qingyun Zhang, Jianjun Xu, Lijuan Guo, Xuefeng Li

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Clinical Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, China

Corresponding to: Qingyun Zhang, PhD., MD. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Clinical Laboratory, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. Email: zhqy_208@163.com.

Objective: MicroRNA-21 (miR-21) has been shown to be a key regulator of carcinogenesis. There were few reports about the comparison of serum miR-21 with conventional tumor markers. This study aimed to explore the diagnostic value of circulating miR-21 as a tumor marker in breast cancer (BC) and compare it with CA153 and carcinoembryonic antigen (CEA).

Methods: Circulating miR-16 and miR-21 were amplified and quantitatively detected by real-time PCR in 89 BC patients and 55 healthy controls. The levels of CA153 and CEA were measured through electrochemiluminescence assays. Then the sensitivity in diagnosis of BC was compared among miR-21, CA153 and CEA.

Results: The level of serum miR-21 was significantly higher in BC patients than controls (P<0.001). The sensitivity and specificity of miR-21 were 87.6% and 87.3%, respectively, whereas the sensitivities of CEA and CA153 were only 22.47% and 15.73%.

Conclusions: Compared with CEA and CA153, serum miR-21 has a higher sensitivity in diagnosis of BC. Although not correlated with the status of ER, PR and clinical stages, serum miR-21 may be a potential diagnostic indicator for BC, especially for the early stage.

Keywords: MicroRNA-21 (miR-21); breast cancer (BC); real-time polymerase chain reaction (real-time PCR)

Submitted Mar 7, 2013. Accepted for publication Oct 13, 2013.
Scan to your mobile device or view this article at: http://www.thecjcr.org/article/view/3080/3982

Introduction

Breast cancer (BC) is the most common cancer among women. Stage at diagnosis is an important predictor of BC survival and quality of life, so there is an urgent need for diagnostic indicators. With simpleness, rapidness and noninvasiveness, tumor markers are playing an increasingly important role in BC diagnosis and treatment.

The most commonly used markers for BC are cancer antigen 153 (CA153) and carcinoembryonic antigen (CEA). However, the specificity and sensitivity of them are low. MicroRNAs (miRNAs) are a class of noncoding RNAs of 19-25 nucleotides that have been implicated in regulating diverse cellular processes. They have a close relationship with tumor formation and development. miR-21 is significantly elevated in the majority of human tumors. It plays an important role in tumor formation and development, and it has been shown to be a key regulator of oncogenic processes. Iorio et al. (1) had reported that miR-21 is overexpressed in BC tissue, and it may be a useful marker of BC. But it is invasive to get tissue. The serum sample has the advantages of simple collection, less invasiveness, and easy monitoring. We have evaluated the expression of miR-21 by stem-loop real-time reverse transcription-polymerase chain reaction (RT-PCR) based on SYBR-Green using miR-16 as reference in 89 BC patients and 55 healthy controls. Levels of miR-21 expression by disease stage and hormone receptor status were compared. Then the sensitivity was compared among miR-21, CA153 and CEA in diagnosing BC.
Materials and methods

Subjects

During the study, all tumor serum samples were collected consecutively from patients who underwent therapy for BC in Beijing Cancer Hospital between March 2011 and May 2011. All patients included in the study had a histologically confirmed diagnosis of primary BC, aged from 29 to 80 years, and the median age was 56 years. All normal human serum samples were collected from healthy women who underwent a medical examination in Beijing Cancer Hospital between March 2011 and April 2011, aged from 28 to 65 years, and the median age was 50 years. This study was approved by the Ethic Committee of Beijing Cancer Hospital, and written informed consent of all the patients was obtained.

Detection of miR-21

Serum samples and preparation of total RNA

Fresh serum samples were stored at –80 °C until processing. Total RNAs were extracted from serum using TRIzol reagent (Invitrogen life technologies) according to the manufacturer’s instructions.

Reverse transcription

Each RNA sample of 10 μL was mixed with 3 μL stem-loop RT primers of miR-21 and miR-16, and 4 μL of 5x RT Buffer, 2 μL of 1 mol/L dithiothreitol [DTT; Tiangen Biotech (Beijing) Co., Ltd.], 0.2 μL of RNasin [Tiangen Biotech (Beijing) Co., Ltd.], 0.5 μL of dNTPs [Tiangen Biotech (Beijing) Co., Ltd.], and 1 μL of Moloney murine leukemia virus (M-MLV) reverse transcriptase [Promega (Beijing) Biotech Co., Ltd.] were added (Table 1). miR-16 was used as an endogenous control. The mixture in a final volume of 20.7 μL was incubated at 16 °C for 30 min, 37 °C for 30 min and 70 °C for 10 min, and then held at 4 °C.

Real-time PCR

After reverse transcription, 1.6 μL cDNA product along with 1 μL PCR primers and 10 μL SYBR Green Master (Roche Co., Ltd.) were mixed with other PCR reagents (Table 2). The PCR conditions included denaturing at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The reaction was carried out in the ABI 7500 Fast PCR system.

Detection of CA153 and CEA

The levels of CA153 and CEA were measured through electrochemiluminescence assays. The reaction was carried out in a Roche E170 MODULAR Immunoassay Analyzer.

Statistical analysis

The expression of circulating miR-21 was normalized through relative change folds. The relative expression levels of miR-21 were characterized by their median and ranges from the 25th to the 75th percentile. The associations of miR-21 with patients’ clinical stage were analyzed with the Kruskal-Wallis test, and the associations of miR-21 with hormone receptor status were analyzed with the Mann-Whitney test. The expression of miR-21 in BC and healthy control was also calculated using the Mann-Whitney test. The cut-off value was determined via receiver operating characteristic (ROC) curve, and then the sensitivity and specificity of diagnosis were obtained according to the cut-off value. P<0.05 was considered statistically significant, and all statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).

Results

Amplification of target gene

The melting curves of miR-21 and miR-16 were sharply defined curves with a narrow peak, indicating that pure,
homogeneous PCR products were obtained (Figure 1). The amplification curves are shown in Figure 2.

miR-21 expression in BC

We have evaluated the expression of miR-21 in 89 BC patients and 55 healthy controls. The relative expression of miR-21 in BC (30.82) was significantly higher than that in healthy controls (9.1) (P<0.001) with the ratio of 3.39 (Figure 3).

ROC curve for miR-21

The best cut-off value was 13.22, the area under ROC curve (ROC-AUC) was 92.9% (95% confidence interval: 88.3%, 97.4%), and the sensitivity and specificity were 87.6% and 87.3%, respectively (Figure 4).

Association of miR-21 expression with clinical and pathological features

Table 3 shows the median expression of miR-21 in various groups of patients classified by clinical stage and hormone
receptors status. Correlations of miR-21 with the clinical and pathological features were not observed, including clinical stage and hormone receptors status (P>0.05).

Comparison of miR-21 with conventional tumor markers CA153 and CEA

Table 4 shows the median expression of miR-21, CA153 and CEA in various groups of patients classified by different clinical stage. The overall sensitivity of miR-21 was 87.64%, while the overall sensitivity of CA153 and CEA was only 22.47% and 15.73%, respectively. Besides, serum miR-21 also has higher sensitivity (95.24%) in the diagnosis of early-stage (stage I) BC compared with CA153 and CEA (4.76%) (Table 4).

Discussion

miRNAs are small, non-coding RNA molecules of 19-25 nucleotides in length which participated in the regulation of a variety of biological signaling pathways (2). Many studies have found that miRNA closely related to the development, invasion, metastasis and other characteristics of tumors, which showed the possibility to be the foundation of a new strategy for cancer therapy (3). The abnormal expression of miRNA in tissue or serum was closely related to a variety of malignant tumors (4,5). It is getting more and more attention as a new marker for tumor diagnosis and prognosis.

BC is the most common cancer in women, and early diagnosis and treatment of BC has important prognostic significance. Serum markers have become increasingly important to diagnosis of BC for its simple collection and less invasiveness. CA153 and CEA are the most widely used markers in monitoring patients with BC, and elevated serum levels are associated with BC relapse, but both lack of sensitivity for early-stage disease and specificity (6). What is more, CEA is a non-specific tumor marker and has a lower positive rate in early diagnosis of BC. It cannot serve as an indicator of early diagnosis of BC (7).

Currently, some miRNAs have been found differentially expressed in BC and normal tissues, such as miR-145 (1), miR-21 and let-7a (8). They play different roles in cell proliferation and apoptosis, and regulate biological processes of BC cells. Recently, it have been reported miRNA could be a tumor maker for the diagnosis and treatment of BC (9).

miR-21 located in 17q23.2, and has independent transcriptional units (10). It participated in regulating the expression of multiple tumor suppressor genes, and played an important role in the development of colon cancer (11,12), lung cancer (13,14), stomach cancer (15), BC (1,16,17) et al. Several studies have proved miR-21 was up-regulated in BC both in vivo and in vitro by different kinds of methods including Northern blotting (1), microarray

| Table 3 Association of miR-21 expression with clinical and pathological features |
|-----------------|-----------------|-----------------|-----------------|
| Variable        | N               | Expression of miR-21 [median (range)] | P               |
| Clinical stage  |                 |                               |                 |
| I               | 21              | 35.91 (24.81-52.57)             | 0.199           |
| II              | 28              | 25.34 (17.33-37.00)             | 0.023           |
| III             | 9               | 30.82 (24.94-40.94)             | 0.199           |
| IV              | 31              | 35.37 (23.68-50.85)             | 0.199           |
| ER              |                 |                               |                 |
| Negative        | 23              | 35.91 (18.48-49.18)             | 0.925           |
| Positive        | 66              | 30.15 (23.20-48.34)             |                 |
| PR              |                 |                               |                 |
| Negative        | 28              | 36.18 (19.04-49.90)             | 0.811           |
| Positive        | 61              | 30.09 (22.87-48.58)             |                 |

| Table 4 Association of miR-21, CA153 and CEA expression with clinical stage |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Clinical stage  | N               | miR-21 Expression | Positive rate (%) | CA153 Expression | CEA Expression | Positive rate (%) |
|                 |                 | [median (range)]  |                   | [U/mL]           | [ng/mL]        |                   |
| I               | 21              | 35.91 (24.81-52.57) | 95.24 (20/21)     | 10.80 (7.68-12.55) | 1.43 (1.00-2.01) | 4.76 (1/21)     |
| II              | 29              | 25.34 (17.33-37.00) | 82.14 (23/28)     | 9.94 (6.90-15.37) | 1.85 (1.39-2.30) | 3.57 (1/28)     |
| III             | 9               | 30.82 (24.94-40.94) | 88.89 (8/9)       | 12.01 (10.82-19.16) | 1.95 (1.67-2.68) | 0 (0/9)         |
| IV              | 30              | 35.37 (23.68-50.85) | 87.10 (27/31)     | 23.43 (12.72-41.17) | 4.48 (3.23-16.43) | 38.71 (12/31)  |
| Total           | 89              | 30.82 (21.65-48.99) | 87.64 (78/89)     | 12.09 (8.01-22.53) | 2.12 (1.52-3.96) | 15.73 (14/89)   |
(1,18), bead-based flow cytometric miRNA expression profiling method (19), in situ hybridization (ISH) (16), and real-time RT-PCR (20-23), and a preliminary study has been taken about the overexpression of miR-21 in BC tissue (1,21,24-26). The results showed that the expression level of miR-21 in tumor samples was higher than that in the normal breast samples, and the expression of miR-21 was associated with some clinical and pathological variables (27). But, there was no evaluation and in-depth discussion of its application in BC diagnosis. Furthermore, all previous studies were about BC tissue, and there were few studies about serum miR-21. We have evaluated the expression of miR-21 by stem-loop real-time RT-PCR based on SYBR-Green in serum of BC patients, and evaluated the value of miR-21 as a diagnostic indicator to discuss its role as a serum marker in BC diagnosis and treatment monitoring. The results showed that the level of serum miR-21 was significantly higher (about 3.39 times) in BC patients than in controls (P<0.001). The sensitivity and specificity of miR-21 in the diagnosis of BC were 87.6% and 87.3%, respectively, whereas the sensitivities of CA153 and CEA were only 22.47% and 15.73%. Besides, no significant association was found between expression of miR-21 in serum and clinical stages, and there was also no significant association between expression of miR-21 in serum and the status of estrogen receptor (ER) and progesterone receptor (PR). This result was consistent with other reports (21,24).

In conclusion, miR-21 is a more sensitive marker for BC compared with CA153 and CEA. It can improve the early diagnosis of BC, thereby improving the prognosis of BC. miR-21 is a potential tumor marker in the diagnosis of early-stage BC. The preliminary study was carried out. In the follow-up study, we will expand the sample size, and take more in-depth analysis. It will lay a good foundation for serum miR-21 detection in diagnosis of BC.

Acknowledgements

This study was supported by National High-Tech Research and Development (863) Program of China (No. 2012AA02A504).

Disclosure: The authors declare no conflict of interest.

References

